Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New ALS drug tested for safety in small trial

NCT ID NCT04632225

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 26 times

Summary

This study tested the safety of an experimental drug called engensis in 18 people with amyotrophic lateral sclerosis (ALS), a disease that weakens muscles over time. Participants received either engensis or a placebo injection into their muscles. The main goal was to check for side effects, while also exploring whether the drug might help with muscle strength, daily function, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Austin Neuromuscular Center

    Austin, Texas, 78759, United States

  • Hanyang University Medical Center

    Seoul, 04763, South Korea

  • Johns Hopkins University Department of Neurology

    Baltimore, Maryland, 21205, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • St. Joseph's Hospital and Medical Center, Barrows Neurological Institute

    Phoenix, Arizona, 85013, United States

Conditions

Explore the condition pages connected to this study.